Aurora kinase inhibitor patents and agents in clinical testing: An update (2011-2013)

Chun Hei Antonio Cheung, Sailu Sarvagalla, Jane Ying Chieh Lee, Yi Chun Huang, Mohane Selvaraj Coumar

Research output: Contribution to journalReview articlepeer-review

48 Citations (Scopus)


Introduction: Aurora kinase A, B and C, members of serine/threonine kinase family, are key regulators of mitosis. As Aurora kinases are overexpressed in many of the human cancers, small-molecule inhibitors of Aurora kinase have emerged as a possible treatment option for cancer. Areas covered: In 2009 and 2011, the literature pertaining to Aurora kinase inhibitors and their patents was reviewed. Here, the aim is to update the information for Aurora kinase inhibitors in clinical trials and the patents filed between the years 2011 and 2013. Pubmed, Scopus®, Scifinder®, USPTO, EPO and databases were used for searching the literature and patents for Aurora kinase inhibitors. Expert opinion: Even though both Aurora sub-type selective as well as pan-selective inhibitors show preclinical and clinical efficacy, so far no Aurora kinase inhibitor has been approved for clinical use. Particularly, dose-limiting toxicity (neutropenia) is a key issue that needs to be addressed. Preliminary evidence suggests that the use of selective Aurora A inhibitors could avoid Aurora B-mediated neutropenia in clinical settings. Also, use of adjunctive agents such as granulocyte stimulating factor to overcome neutropenia associated with Aurora B inhibition could be an answer to overcome the toxicity and bring Aurora inhibitors to market in the future.

Original languageEnglish
Pages (from-to)1021-1038
Number of pages18
JournalExpert Opinion on Therapeutic Patents
Issue number9
Publication statusPublished - 2014 Sept

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Aurora kinase inhibitor patents and agents in clinical testing: An update (2011-2013)'. Together they form a unique fingerprint.

Cite this